A Phase II Clinical Study Evaluating the Efficacy and Safety of CM338 Injection in Subjects With Immunoglobulin A Nephropathy
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This study is a multicenter, randomized phase II clinical study to evaluate Efficacy and safety, while observing pharmacokinetic profiles, pharmacodynamic effects, and immunogenicity of CM338 in subjects with Immunoglobulin A(IgA) nephropathy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Male or female aged 18-75.
• Understand the nature of the study and sign the Informed Consent Form voluntarily.
• Take effective contraception measures throughout the study period.
Locations
Other Locations
China
Peking University First Hospital
RECRUITING
Beijing
Contact Information
Primary
Qian Jia
qianjia@keymedbio.com
028-88610620
Time Frame
Start Date: 2023-05-08
Estimated Completion Date: 2027-06-30
Participants
Target number of participants: 70
Treatments
Experimental: Group A
CM338 will be injected subcutaneously.
Experimental: Group B
CM338 will be injected subcutaneously.
Experimental: Group C
CM338 will be injected subcutaneously.
Related Therapeutic Areas
Sponsors
Leads: Keymed Biosciences Co.Ltd